Go Pro
NASDAQ:BTTC

Black Titan Q1 2026 Earnings Report

Black Titan logo
$0.36 0.00 (-0.96%)
As of 11:19 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Black Titan EPS Results

Actual EPS
-$1.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Black Titan Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Black Titan Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Black Titan Earnings Headlines

Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades near 4,500 dollars today, a 113-to-1 gap between book value and market reality. Treasury Secretary Scott Bessent has said he wants to monetize the asset side of the balance sheet. A revaluation could add more than 1 trillion dollars to the government's books overnight. Certain gold miners still trade as if gold were under 2,000 dollars, even as prices near record highs.tc pixel
See More Black Titan Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Titan? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Titan and other key companies, straight to your email.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

View Black Titan Profile